Skip to main content

Letter to Shareholders Regarding Rafarma Acquisition by R. & D. Biocogency Laboratories Inc.

Written by Customer Service on . Posted in Public Companies.

Ljubljana, Slovenia, Aug. 05, 2020 (GLOBE NEWSWIRE) — Rafarma Pharmaceuticals, Inc. OTC:(RAFA) presents the following letter to Rafarma shareholders from CEO Vladimir Dolgolenko:
To Our Shareholders:During these exciting times I wanted to reach out to our shareholders and clarify some questions I have received. As recently announced, there will be a change in control forthcoming for Rafarma. The change in control will not affect the current share structure of the company. There has been no dilution and there are no current plans for dilution or issuance of additional shares as part of this acquisition. Our acquirer, R&D Biocogency Laboratories Inc. (“Biocogency”), brings an enormous amount of potential and an already proven business model. As stated in our previous release, Biocogency’s 2019 revenues were approximately $73 million with profits at approximately $17 million. We intend to both harness and grow these profits and further our expansion throughout Europe and Asia.Thailand operations are continuing as planned and will only be improved with this new infusion of capital and more research opportunities. Our strategic partners are extremely excited with the progress that has been made in recent months.This is also the first of what we believe will be several merger and acquisition activities. As we acquire additional companies and facilities, we believe shareholder value will increase immensely. As CEO I want to thank shareholders for their patience and their trust in Rafarma. I believe we are building a strong company with unlimited potential as we move forward.Kinds regards,
Vladimir Dolgolenko,
CEO, Rafarma Pharmaceuticals, Inc.Forward-Looking Statements: This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934. Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate,” or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements. Forward-looking statements involve known and unknown risk, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in the Company’s filings with OTC Markets. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.For more information contact:
RAFARMA
(307) 429-2029

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.